Mineralys Therapeutics, Inc.MLYS stock score: 31/100

$14.16 · +2.76% · Scored Nov 19, 2026

Technical
23
Fundamental
33
News
—

The reading

Mineralys Therapeutics (MLYS) scores 31 out of 100, which reads bearish, higher than 5% of Healthcare stocks and 6% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 33, technicals 23.

Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Free Cash Flow Yield at 0 weighs the most against it.

On the daily chart, trend-following indicators average 10 and contrarian oscillators 73 — a split worth reading before trusting the technical total.

Since Aug 22, 2026 the composite has ranged from 30 to 48, and it is down 12 points over the period.

About Mineralys Therapeutics

Mineralys Therapeutics (MLYS) is a clinical-stage biopharmaceutical company developing treatments for hypertension, chronic kidney disease and related conditions driven by excess aldosterone, a hormone that raises blood pressure. Its lead candidate, lorundrostat, is a once-daily oral drug designed to block aldosterone synthase, the enzyme that makes aldosterone, while largely sparing production of cortisol. In late-stage trials, lorundrostat lowered blood pressure in adults with uncontrolled or resistant hypertension when added to existing medicines, and it has also been studied in patients with chronic kidney disease. A trial in obstructive sleep apnea did not meet its main goal. Mineralys has no product revenue and funds operations with cash raised from investors.

In hypertension, Mineralys would compete with many generic blood pressure drugs and with AstraZeneca’s baxdrostat, another aldosterone synthase inhibitor, as well as with other new treatments for resistant hypertension. Its edge rests on a selective mechanism that targets a common cause of hard-to-control high blood pressure and on data from several positive trials. Investors who follow MLYS stock tend to watch the regulatory process and commercial plans for lorundrostat. Data in kidney disease and other indications are closely followed. Partnering, pricing, competition from baxdrostat and cash runway are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward MLYS’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

33

Pulling it up

  • Quick ratio measures a company's ability to meet short-term obligations with liquid assets.

  • Price target score compares the current stock price to analyst consensus targets.

  • Current assets divided by current liabilities: the ability to pay short-term bills.

Holding it back

  • Free cash flow yield is free cash flow divided by market value: the cash a business generates for each dollar of its price.

  • Return on Equity (ROE) measures how efficiently a company generates profits from shareholder equity.

  • Net income growth against the same quarter a year earlier, weighted toward the latest quarter.

26 weighted scorers; 13 had no data today and are left out rather than counted as zero.

Technical · daily

19

Pulling it up

  • Candlestick patterns recognize specific price formations that historically suggest continuation or reversal.

  • Relative Strength Index (14-period) measures momentum by comparing recent gains to losses.

  • Money Flow Index (14-period) is a volume-weighted RSI that identifies overbought and oversold conditions.

Holding it back

  • S&P 500 52-week comparison evaluates the stock's annual performance relative to the broader market.

  • The price change over the last 52 weeks.

  • Where the price sits between its 52-week low and high.

62 weighted scorers; 3 had no data today and are left out rather than counted as zero.

Technical score by timeframe

ChartScoreWeight
Hourly381
Daily193
Weekly222

Composite score, last 90 days

05010031Aug 22, 2026Nov 19, 2026Aug 22, 2026: 43Aug 23, 2026: 43Aug 24, 2026: 42Aug 25, 2026: 43Aug 26, 2026: 43Aug 27, 2026: 44Aug 28, 2026: 41Aug 29, 2026: 39Aug 30, 2026: 38Aug 31, 2026: 39Sep 1, 2026: 41Sep 2, 2026: 46Sep 3, 2026: 46Sep 4, 2026: 45Sep 5, 2026: 46Sep 6, 2026: 46Sep 7, 2026: 44Sep 8, 2026: 48Sep 9, 2026: 47Sep 10, 2026: 45Sep 11, 2026: 44Sep 12, 2026: 44Sep 13, 2026: 44Sep 14, 2026: 45Sep 15, 2026: 45Sep 16, 2026: 42Sep 17, 2026: 43Sep 18, 2026: 42Sep 19, 2026: 43Sep 20, 2026: 43Sep 21, 2026: 44Sep 22, 2026: 46Sep 23, 2026: 44Sep 24, 2026: 40Sep 25, 2026: 36Sep 26, 2026: 38Sep 27, 2026: 37Sep 28, 2026: 37Sep 29, 2026: 36Sep 30, 2026: 37Oct 1, 2026: 35Oct 2, 2026: 35Oct 3, 2026: 36Oct 4, 2026: 36Oct 5, 2026: 35Oct 6, 2026: 34Oct 7, 2026: 34Oct 8, 2026: 35Oct 9, 2026: 36Oct 10, 2026: 36Oct 11, 2026: 36Oct 12, 2026: 34Oct 13, 2026: 33Oct 14, 2026: 33Oct 15, 2026: 34Oct 16, 2026: 32Oct 17, 2026: 33Oct 18, 2026: 33Oct 19, 2026: 34Oct 20, 2026: 34Oct 21, 2026: 34Oct 22, 2026: 35Oct 23, 2026: 33Oct 24, 2026: 33Oct 25, 2026: 34Oct 26, 2026: 33Oct 27, 2026: 35Oct 28, 2026: 34Oct 29, 2026: 35Oct 30, 2026: 31Oct 31, 2026: 32Nov 1, 2026: 33Nov 2, 2026: 31Nov 3, 2026: 31Nov 4, 2026: 32Nov 5, 2026: 30Nov 6, 2026: 31Nov 7, 2026: 31Nov 8, 2026: 31Nov 10, 2026: 32Nov 11, 2026: 33Nov 12, 2026: 30Nov 13, 2026: 32Nov 14, 2026: 32Nov 15, 2026: 32Nov 16, 2026: 31Nov 17, 2026: 31Nov 18, 2026: 30Nov 19, 2026: 31
Show the daily numbers
DateComposite
Nov 19, 202631
Nov 18, 202630
Nov 17, 202631
Nov 16, 202631
Nov 15, 202632
Nov 14, 202632
Nov 13, 202632
Nov 12, 202630
Nov 11, 202633
Nov 10, 202632
Nov 8, 202631
Nov 7, 202631
Nov 6, 202631
Nov 5, 202630
Nov 4, 202632
Nov 3, 202631
Nov 2, 202631
Nov 1, 202633
Oct 31, 202632
Oct 30, 202631
Oct 29, 202635
Oct 28, 202634
Oct 27, 202635
Oct 26, 202633
Oct 25, 202634
Oct 24, 202633
Oct 23, 202633
Oct 22, 202635
Oct 21, 202634
Oct 20, 202634
Oct 19, 202634
Oct 18, 202633
Oct 17, 202633
Oct 16, 202632
Oct 15, 202634
Oct 14, 202633
Oct 13, 202633
Oct 12, 202634
Oct 11, 202636
Oct 10, 202636
Oct 9, 202636
Oct 8, 202635
Oct 7, 202634
Oct 6, 202634
Oct 5, 202635
Oct 4, 202636
Oct 3, 202636
Oct 2, 202635
Oct 1, 202635
Sep 30, 202637
Sep 29, 202636
Sep 28, 202637
Sep 27, 202637
Sep 26, 202638
Sep 25, 202636
Sep 24, 202640
Sep 23, 202644
Sep 22, 202646
Sep 21, 202644
Sep 20, 202643
Sep 19, 202643
Sep 18, 202642
Sep 17, 202643
Sep 16, 202642
Sep 15, 202645
Sep 14, 202645
Sep 13, 202644
Sep 12, 202644
Sep 11, 202644
Sep 10, 202645
Sep 9, 202647
Sep 8, 202648
Sep 7, 202644
Sep 6, 202646
Sep 5, 202646
Sep 4, 202645
Sep 3, 202646
Sep 2, 202646
Sep 1, 202641
Aug 31, 202639
Aug 30, 202638
Aug 29, 202639
Aug 28, 202641
Aug 27, 202644
Aug 26, 202643
Aug 25, 202643
Aug 24, 202642
Aug 23, 202643
Aug 22, 202643

Key facts

Market cap
$1.3B
Sector
Healthcare
Industry
Biotechnology
Beta
0.82
Risk grade (1–10)
9
Next earnings
Nov 4, 2026

Questions

What is MLYS's stock rating today?

MLYS scores 31/100 (Bearish) as of Nov 19, 2026: technical 23, fundamental 33. Scores are recomputed every night.

What does Mineralys Therapeutics do?

Mineralys Therapeutics (MLYS) is a clinical-stage biopharmaceutical company developing treatments for hypertension, chronic kidney disease and related conditions driven by excess aldosterone, a hormone that raises blood pressure. Its lead candidate, lorundrostat, is a once-daily oral drug designed to block aldosterone synthase, the enzyme that makes aldosterone, while largely sparing production of cortisol.

Is MLYS stock a buy?

The score is not a buy or sell recommendation. A 31 says the technical and fundamental signals we measure lean bearish today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the MLYS score calculated?

88 weighted scorers feed it today: 26 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

MLYS stock score

HTML

<a href="https://stocksscores.com/stocks/mlys/"><img src="https://stocksscores.com/stocks/mlys/badge.svg" alt="MLYS stock score" height="20"></a>

Markdown

[![MLYS stock score](https://stocksscores.com/stocks/mlys/badge.svg)](https://stocksscores.com/stocks/mlys/)